Gather data from every child, adolescent, cancer, regardless of where they receive In the United States, COG engages its Rare Tumor Committee and adolescents (30). These include tumors classified within and melanomas—such as adrenocortical, nasopharyngeal, colorectal (CRC), and thyroid cancers; melanoma; pleuropulmonary blastoma; retinoblastoma; gonadal stromal, pancreatoblastoma, and gastrointestinal stromal tumors; non-melanoma skin cancers; neuroendocrine tumors; and will improve prevention, treatment, quality of desmoplastic small round cell tumors (26,30). Collectively, life, and survivorship for pediatric cancers. Within the pediatric population, some cancers (i.e., thyroid and CRC) are more common in adolescents than children. As one example, although only about 5 in 1 million children in the United States are diagnosed with CRC annually (5,11,16), they (31). Despite presenting with disease that resembles early-onset community, including advocates, pediatric CRC in adults, children are 22 percent more likely to die from the disease than adults diagnosed between ages 22 and 50 (31). researchers, data scientists, children and of the tumor rather than disparate treatment modalities (31). molecular profiling, development of tailored therapies, improvements in survival for children with CRC. against rare pediatric cancers, such as detailed information on tumor biology, COG collects patient samples (e.g., blood, tumor tissues, and urine) to advance the development of targeted therapies. Through its biospecimen collection initiative, Project:EveryChild, partially supported by NCI, COG gathers samples from patients with all types of pediatric cancer. In 2022, NCI further expanded efforts with the Molecular